This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Please provide your email address to receive an email when new articles are posted on . At any given PSA level, Black men are more likely than white men to harbor prostate cancer, according to ...

Clinical Trials—Real-World Data to Build a Future for Our Patients In the article that accompanies this editorial, Kwak et al 6 demonstrate using individual patient data from randomized trials that ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...